ESCMID Online Lecture Library. by author

Similar documents
Update on global guidelines. and emerging issues on perinatal HIV prevention. WHO 2013 Consolidated ARV Guidelines

C E L I A J. M A X W E L L, M. D

Where are we going after effectiveness studies?

Tunisian recommendations on ART : process and results

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

Fertility Desires/Management of Serodiscordant HIV + Couples

HIV in Zambia MINISTRY OF HEALTH. Dr Albert Mwango, BScHB, MBChB, MPH National Antiretroviral Program Coordinator,

What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women

Counselling Should: Recognize that behaviour change is difficult and human beings are not perfect

DEPARTMENT. Treatment Recommendations for. Pregnant and Breastfeeding Women: Critical Issues Consolidated ARV Guidelines. Dr.

Dr Valérie Martinez-Pourcher

M2010 Pre-Conference Workshop, Pittsburgh 22 May 2010

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence

HIV In South Africa: Turning the Tide of the Epidemic

PrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.

treatment during pregnancy and breastfeeding

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:

Combination prevention: Public health and human rights imperatives

Pregnancies amongst adolescents and young women 16% of all births - 19% will have repeat pregnancies before age 20

Update on ARV based PrEP

Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi

MANAGEMENT OF SEXUAL EXPOSURE TO HIV: PEPSE

Using anti-hiv drugs for prevention

Evolving HIV Treatment Paradigms What we need to know

Sexually Transmitted Infections in Vulnerable Groups. Kevin Rebe

Marijn de Bruin University of Amsterdam Amsterdam School of Communication Research / ASCoR

The Latest on HIV Testing. Dominika Seidman, MD MAS

Updates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013

2016 Perinatal Treatment Guidelines Update

Medical Challenges of HIV/AIDS pandemic: The WHO perspective. SOLTHIS HIV Forum

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

ART and Prevention: What do we know?

No Conflict of Interest

11/8/2016. The Challenge of HIV Treatment

Family Planning and Sexually Transmitted. Infections, including HIV

Understanding the Results of VOICE

I M ENDING HIV PATIENT INFORMATION. endinghiv.org.au/prep

Overview of 2013 WHO consolidated ARV guidelines and update plans. Marco Vitoria HIV/AIDS Department WHO Geneva September 2014

Receptive Anal Intercourse and HIV Infection

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

Guidelines for Implementing Pre-Exposure Prophylaxis For The Prevention of HIV in Youth Peter Havens, MD MS Draft:

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010

Program to control HIV/AIDS

Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention

Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know

HIV and Paediatrics in Central Europe

PrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

The Beginning of the End of AIDS Diane V. Havlir, MD

HIV and contraception the latest recommendations

Informed Consent Flipchart. Version 1.0, 30 Jan 2018

HIV Clinical Update- HIV prevention

The Global HIV Epidemic: Women in Africa and Haiti

WOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society

HIV/AIDS MODULE. Rationale

The Evidence Base for Women

Management of HIV Infected Children and Adolescents: Public Sector Approach in Kenya

The Global State of HIV/AIDS. Presented By: Siobhan K. Young, MPH PhD Candidate at UNC Chapel Hill

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings.

Training of Peer Educator Ujenzi

What you need to know to: Keep Yourself SAFE!

PRECONCEPTION COUNSELING

HIV Prevention. Recent Advances and Implications for the Caribbean

HIV AND AIDS FACT SHEETS

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital

Patient factors to target for emtct. CN Mnyani 25 September 2014

PrEP for HIV prevention. Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint

versus CD4. PoC - Messaging - Specificity and - Ethics sensitivity of HIV - Feedback from diagnostic tests demonstration projects

QUESTIONS AND ANSWERS

PrEP May Cause a Revolution in HIV Prevention: Time to Get Ready

ADOLESCENT TREATMENT LITERACY GUIDE: FLIP CHART

ART for HIV Prevention:

Biomedical Prevention in HIV

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

MTN 034/IPM 045: REACH Rings and PrEP in Young Women

HIV PREVENTION. ETHICAL CONSIDERATIONS IN DEVELOPING AN EVIDENCE BASE FOR PrEP IN PREGNANT WOMEN

Linkages between Sexual and Reproductive Health and HIV

The role of Integrase Inhibitors during HIV prevention

Elements of Reproductive Health

PrEP and npep for HIV Prevention. Harry Rosado-Santos MD, FACP Associate Professor UU School of Medicine

AIDS. health concern. As of 2005, a cure for HIV/AIDS remains to be found. While medical

Fertility Management in HIV. INTEREST Workshop, 16 Dakar May 2013 Vivian Black, Director Clinical Programmes Wits Reproductive Health & HIV Institute

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

Prevention and care towards vulnerable and stigmatized populations (MSM, drug users, sex workers)

Medical Case Management Training Series Module 1. Anissa Ray & Vadim Kogan

Goal of this chapter. 6.1 Introduction Good practices for linkage to care General care for people living with HIV 84

HIV and Older Adults: An Online Course for Health and Social Service Providers

HIV, Aging, and Frailty: Cannonball?

Sexually Transmitted Infections. Kim Dawson October 2010

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel

Understanding contraceptive choices among a cohort of HIV-positive women

Appendix 1: summary of the modified GRADE system (grades 1A 2D)

HPV Transmission. Rachel Winer, PhD, MPH Department of Epidemiology University of Washington

HIV Treatment as Prevention (TasP)

International Partnership for Microbicides

Understanding Epidemics Section 2: HIV/AIDS

GLOBAL AIDS MONITORING REPORT

Transcription:

Improving Patient Safety: the Neglected Impact of Age and Gender, ESCMID Postgraduate Technical Workshop HIV in men, women and elderly Juan Ambrosioni MD, PhD

Content HIV in men and women: differences and similarities -Transmission, prevention, treatment -Timing of HIV diagnosis: Early vs. Late presentation -Not all men are equal for HIV: MSM vs. Heterosexuals -Specific vulnerable women populations (elderly, adolescents) HIV and age -HIV-positive patients, an aging population: reasons -Effect of HIV on aging (immunity, metabolic, neoplastic) -Effect of aging on HIV Conclusions and take-home messages

Content HIV in men and women: differences and similarities -Transmission, prevention, treatment -Timing of HIV diagnosis: Early vs. Late presentation -Not all men are equal for HIV: MSM vs. Heterosexuals -Specific vulnerable women populations (elderly, adolescents) HIV and age -HIV-positive patients, an aging population: reasons -Effect of HIV on aging (immunity, metabolic, neoplastic) -Effect of aging on HIV Conclusions and take-home messages

HIV in men and women: are available data applicable to women? HIV cure studies, but it happens with all studies Johnston et al. AIDS Res Hum Retrov. 2015

Content HIV in men and women: differences and similarities -Transmission, prevention, treatment -Timing of HIV diagnosis: Early vs. Late presentation -Not all men are equal for HIV: MSM vs. Heterosexuals -Specific vulnerable women populations (elderly, adolescents) HIV and age -HIV-positive patients, an aging population: reasons -Effect of HIV on aging (immunity, metabolic, neoplastic) -Effect of aging on HIV Conclusions and take-home messages

-Transmission, prevention, treatment For a given sexual intercourse, always higher risk of transmission for the receptive partner (anal > vaginal > oral, always higher if ejaculation) -A man can be insertive or receptive, but a woman is always receptive -However, in many settings (e.g. BCN) epidemics is driven by MSM (PHI) Varghese B, et al. Sex Transm Dis. 2002

-Transmission, prevention, treatment Effective measures to decrease female-to-male transmission (circumcision, 3 large RCT in Africa), but not in the other side Microbicides, only modest results, difficult to apply (CAPRISA) In many settings, poor power of decision for women to impose the use of condoms Siegfried et al. Cochrane Syst Rev 2009 Abdool Karim et al. Science 2010

-Transmission, prevention, treatment Abdool Karim et al. Science 2010

-Transmission, prevention, treatment Particular situations SHOULD be considered for therapy in women: PREGNANCY Irrespective of the guideline: ALWAYS PRIORITY FOR TREATMENT. If possible, do not stop ART after delivery. MTCT is less than 1% for women effectively on ART WHO consolidated guidelines 2013

WHO consolidated guidelines 2013 -Transmission, prevention, treatment B+: Lifelong B: al least pregnancy and breastfeeding

-Transmission, prevention, treatment Particular situations SHOULD be considered for therapy in women: D-D interactions, pregnancy desire, comorbidities and toxicities (e.g. osteoporosis) Optimal ARV regimen for women? EFV? Yes or no? It won t be longer contraindicated in next EACS guidelines. Several PI and NNRTI may decrease contraceptive plasmatic levels, thus reducing efficacy Greig et al. Curr Opin Infect Dis, 2014 EACS Guidelines, 2015 (in preparation)

Drug choice for women Although few women in RCT. Higher % of discont. in RCT. More nausea and larger increases in weight with PI. NVP-EFV toxicity. Particularly pregnancy and contraception. Greig et al. Curr Opin Infect Dis, 2014

Content HIV in men and women: differences and similarities -Transmission, prevention, treatment -Timing of HIV diagnosis: Early vs. Late presentation -Not all men are equal for HIV: MSM vs. Heterosexuals -Specific vulnerable women populations (elderly, adolescents) HIV and age -HIV-positive patients, an aging population: reasons -Effect of HIV on aging (immunity, metabolic, neoplastic) -Effect of aging on HIV Conclusions and take-home messages

Antinori et al. HIV Medicine 2011, Breskin et al. Sex Transm Dis. 2015 Timing of HIV diagnosis: Early vs. Late presentation and co-infections Consistently, MSM population is diagnosed at earlier stages compared to heterosexual men and women Late presenters are much more frequent among populations with low perception of risk Several definitions. Largely accepted ( European ): -Late presenters: <350 CD4 cells (+/- opport. event) -Advanced disease: <200 CD4 cells (+/- opport. event) Some infections are rarely transmitted through heterosexual contacts, but frequently among MSM (HCV)

Content HIV in men and women: differences and similarities -Transmission, prevention, treatment -Timing of HIV diagnosis: Early vs. Late presentation -Not all men are equal for HIV: MSM vs. Heterosexuals -Specific vulnerable women populations (elderly, adolescents) HIV and age -HIV-positive patients, an aging population: reasons -Effect of HIV on aging (immunity, metabolic, neoplastic) -Effect of aging on HIV Conclusions and take-home messages

Specific vulnerable women populations (elderly, adolescents) Extreme age groups are at particular risk for acquiring the infection and to neglect the possibilities of being infected Adolescents: in countries with the highest rates of HIV, males dominate sexual decision making. Older women: early menopause, neurocognitive impairment, osteoporosis. Frequently missed by the risk reduction programs Hardee et al. JAIDS 2014 Durvasula. Behav Med 2014

Content HIV in men and women: differences and similarities -Transmission, prevention, treatment -Timing of HIV diagnosis: Early vs. Late presentation -Not all men are equal for HIV: HSH vs. Heterosexuals -Specific vulnerable women populations (elderly, adolescents) HIV and age -HIV-positive patients, an aging population: reasons -Effect of HIV on aging (immunity, metabolic, neoplastic) -Effect of aging on HIV Conclusions and take-home messages

-Not all men are equal for HIV: MSM vs. Heterosexuals Intergenerational sex as a risk factor for HIV in MSM Anema et al. Curr HIV/AIDS Rep, 2013

Content HIV in men and women: differences and similarities -Transmission, prevention, treatment -Timing of HIV diagnosis: Early vs. Late presentation -Not all men are equal for HIV: MSM vs. Heterosexuals -Specific vulnerable women populations (elderly, adolescents) HIV and age -HIV-positive patients, an aging population: reasons -Effect of HIV on aging (immunity, metabolic, neoplastic) -Effect of aging on HIV Conclusions and take-home messages

-HIV-positive patients, an aging population: reasons Inelmen et al. Agin Clin Exp Res, 2014

-HIV-positive patients, an aging population. Approach for care providers. Inelmen et al. Agin Clin Exp Res, 2014

Content HIV in men and women: differences and similarities -Transmission, prevention, treatment -Timing of HIV diagnosis: Early vs. Late presentation -Not all men are equal for HIV: MSM vs. Heterosexuals -Specific vulnerable women populations (elderly, adolescents) HIV and age -HIV-positive patients, an aging population: reasons -Effect of HIV on aging (immunity, metabolic, neoplastic) -Effect of aging on HIV Conclusions and take-home messages

Deeks SG et al. Curr Opin Immunol, 2012 Tsoukas, Curr Opin HIV AIDS, 2014 Senescence and immune senescence Normal cell process, common pathway of many cell lines, characterized by shortened telomeres Immune senescence is associated with a lost of expression of CD28 and increase expression of CD57 Senescent immune cells are: highly differentiated, very limited capacity of proliferation and produce a pro-inflammatory cytokine profile

Senescence and immune senescence Biologically (organism): -increased susceptibility to infection -lost of protection from previous vaccinations -decreased responsiveness to new vaccinations -decreased surveillance against cancer -increased auto-inmmunity - frailty High proportion of CD28- cells and increased chronic inflammation in HIV-infected individuals This immune senescence may be, at least in part, responsible for the non-aids co morbidities Deeks SG et al. Curr Opin Immunol, 2012 Brothers et al. J Infect Dis, 2014

GALT depletion during PHI Undetectable not equal to no virus Deeks SG et al. Curr Opin Immunol 2012 Deeks SG BMJ 2009

-The window-of-opportunity is not very long -Depletion of GALT occurs really early during PHI GALT depletion Fiebig et al, AIDS 2003. McMichael et al, Nat Rev Immun 2010.

HIV-related cognitive disorders, ilicit drugs, ARV (EFV) Smoking, dyslipidemia, ARV (ABC?) Remember: not HIV alone ARV (TDF), malnutrition Hepatotoxic drugs HBV, HCV co-infection, alcohol

Addition of biological, epidemiological and sociological aspects What lacks? The direct association of risk phenotype and HIV/AIDS progression. Tsoukas, Curr Opin HIV AIDS, 2014

On the other side Impaired immunological response to ART in older individuals Linear regression model. Study performed in African adults (N=9800), median age=37, female 60%. Linear regression model. Study performed in African adults (N=8800), median age=35, female 65%. Semeere AS et al, JAIDS 2014. Mutevedzi PC et al. Plos One 2011.

Content HIV in men and women: differences and similarities -Transmission, prevention, treatment -Timing of HIV diagnosis: Early vs. Late presentation -Not all men are equal for HIV: MSM vs. Heterosexuals -Specific vulnerable women populations (elderly, adolescents) HIV and age -HIV-positive patients, an aging population: reasons -Effect of HIV on aging (immunity, metabolic, neoplastic) -Effect of aging on HIV Conclusions and take-home messages

Conclusions and take-home messages Important disparities when considering men and women infected with HIV, or at risk for acquiring HIV Women are more vulnerable (particularly very young and older women) and have more risk of transmission MTCT remains an issue in limited resources settings Late presentation is more frequent for heterosexuals than MSM, but MSM drive epidemics in many places HIV infection is itself an accelerating aging process (more metabolic, neurocognitive and neoplastic risk) driven by chronic inflammation in the context of other contributing factors

What can we do? Disparities among men and women Remember specific needs for women, particularly very young and older women (stigma, vulnerability, pregnancy, drug interactions, contraceptives) Test for HIV EVERY SINGLE PREGNANT WOMEN. TREAT ALL THEM!!! Think the possibility of HIV infection in heterosexual men and women, to avoid late presentation. It s better get upset a patient than losing the diagnosis

What can we do? Reduce the impact of accelerated aging Consider previous co-morbidities and avoid toxicity potentiation If possible, treat HIV infection in the earliest possible stage Always discuss and work with the patient the classic risk factors for cancer, CV, brain, bone and kidney disease Think about co-infections and repeat serologies when appropriate (Ex. HCV for MSM) Always consider ART changes, simplifications or improvements

Questions and discussion Questions, comments, anything? Thank you very much for your attention!